Dermata Therapeutics- Warrants (13/08/2026) Return on Equity

Dermata Therapeutics- Warrants (13/08/2026)'s return on equity stands at -110.75%. That is below the Healthcare sector average of 29.33%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Dermata Therapeutics- Warrants (13/08/2026) sits lower the Healthcare benchmark (29.33%) with a ROE of -110.75%. That is roughly 477.6% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of -110.75% for Dermata Therapeutics- Warrants (13/08/2026) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Dermata Therapeutics- Warrants (13/08/2026)'s ROE evolved across reporting periods, while the comparison chart places DRMAW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Dermata Therapeutics- Warrants (13/08/2026)'s reading of -110.75% (sector avg 29.33%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.